Related Experiment Videos
Inhibitory effects of copper-aspirin complex on platelet aggregation
1Yunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, China.
Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica
|July 1, 1997
Summary
Copper-aspirin complex (CuAsp) more potently inhibits platelet aggregation than aspirin. This effect is linked to reduced cyclooxygenase activity and release of platelet substances.
Area of Science:
- Pharmacology
- Biochemistry
Background:
- Platelet aggregation plays a crucial role in thrombosis.
- Aspirin is a widely used antiplatelet agent, but its efficacy can be limited.
- Novel compounds are being investigated to enhance antiplatelet therapy.
Purpose of the Study:
- To investigate the antiplatelet effects of copper-aspirin complex (CuAsp).
- To compare the efficacy of CuAsp with aspirin in inhibiting platelet aggregation.
Main Methods:
- Platelet aggregation was induced by adenosine diphosphate (ADP) and arachidonic acid (AA) in vitro and in vivo.
- Thromboxane B2 (TXB2) generation and 6-keto-PGF1 alpha levels were measured using radioimmunoassay and fluorophotometry.
- Platelet serotonin (5-HT) release was also assessed.
Main Results:
- CuAsp significantly inhibited AA-induced platelet aggregation, serotonin release, and TXB2 generation in vitro.
- In vivo, CuAsp administration reduced TXB2 levels and increased 6-keto-PGF1 alpha concentrations in plasma.
- CuAsp demonstrated a more potent inhibitory effect on AA-induced aggregation compared to aspirin.
Conclusions:
- CuAsp exhibits potent in vitro and in vivo antiplatelet activity.
- The mechanism involves inhibition of platelet cyclooxygenase and reduced release of active substances.
- CuAsp represents a promising agent for antiplatelet therapy.